Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 25, 2017
Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017
BOSTON, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon ...
October 25, 2017
AIT Therapeutics Announces Third Quarter Financial Results Conference Call/Webcast
NEW YORK, Oct. 24, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), ...
October 25, 2017
Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors
VANCOUVER, Oct. 25, 2017 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the ...
October 25, 2017
Prometic Receives Fast Track Designation for PBI-4050 in Development for Idiopathic Pulmonary Fibrosis (IPF)
LAVAL, QC , Oct. 25, 2017 /CNW/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced that the U.S. Food and Drug Administration (FDA) has granted ...
October 25, 2017
MediWound Appoints Mr. Stephen T. Wills as Chairman to its Board of Directors
YAVNE, Israel, Oct. 25, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe ...
October 25, 2017
Rockwell Update on Calcitriol Post-Approval Manufacturing Submission to FDA
WIXOM, Mich., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), today provided an update on the commercial launch of Calcitriol, stating that the ...
October 24, 2017
CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis
NEWARK, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
October 24, 2017
AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference
Lausanne, Switzerland, - October 24, 2017 -   AC Immune SA (ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today ...
October 24, 2017
U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome
Copenhagen, Denmark, October 24, 2017 - The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation ...
October 24, 2017
BioTime to Announce Third Quarter 2017 Results on November 9, 2017
ALAMEDA, Calif.--(BUSINESS WIRE) -- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced ...
October 24, 2017
Catalyst Biosciences and Mosaic Biosciences Enter into Strategic Collaboration to Develop Intravitreal Anti-Complement Factor 3 (C3) Products for the Treatment of Dry AMD and Other Retinal Diseases
SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), and privately held Mosaic Biosciences, Inc., today announced ...
October 23, 2017
First International Consensus Statement on the Clinical and Therapeutic Management of LHON published in the Journal of Neuro-Ophthalmology
Liestal, Switzerland, October 23, 2017 - Santhera Pharmaceuticals (SANN.SW) announces that the first International Consensus Statement on the Clinical and Therapeutic Management of Leber`s Hereditary Optic Neuropathy (LHON) ...
October 23, 2017
Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
Basel, Switzerland, October 23, 2017 - Basilea Pharmaceutica Ltd. (BSLN.SW) announced today that the sales of the antifungal Cresemba® (isavuconazole) in the United States exceeded the threshold ...
October 23, 2017
TG1050 is Well Tolerated and Induces a Strong Specific Immune Response in Patients with Chronic Hepatitis B
STRASBOURG, France--(BUSINESS WIRE) -- Regulatory News: Transgene (TNG.PA), a biotech company that designs and develops viral-based immunotherapies, announces that the analyses conducted on patients with chronic hepatitis B ...
October 23, 2017
Prometic enters into binding letter of intent to secure USD $80 million (CAD $100 million) line of credit from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.
Laval, Qc , Oct. 23, 2017 /CNW Telbec/ -Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic") announced today that it has entered into a binding letter of ...
October 23, 2017
Reata Announces First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of Friedreich’s Ataxia
IRVING, Texas, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”) today announced the enrollment of the first patient in the ...
October 23, 2017
Soleno Therapeutics Regains Compliance with NASDAQ Listing Requirements
REDWOOD CITY, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
October 23, 2017
Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017
PASADENA, Calif.--(BUSINESS WIRE) -- Arrowhead Pharmaceuticals Inc. (ARWR) today presented data from studies demonstrating promising preclinical safety and efficacy of ARO-AAT, a second-generation investigational medicine for ...
October 23, 2017
Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) Meeting
PALO ALTO, Calif., Oct. 23, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (EIGR) today announced positive interim 24-week data with pegylated interferon lambda (Lambda) in the ...
October 23, 2017
Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017
LIVONIA, Mich., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
Page 106 of 138